Lilly Goes on $20B Buying Spree as It Seeks Next Act

🇺🇸 Bloomberg (US) —

AI Summary

Eli Lilly is undertaking an aggressive acquisition strategy, announcing over $20 billion in purchases during 2026 as it seeks to diversify beyond its successful obesity drug portfolio. This record spending spree signals potential growth and expansion in the pharmaceutical sector.

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Eli Lilly is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise.  (Source: Bloomberg)

Markets Deals Health Eli Lilly acquisitions pharmaceuticals obesity drugs spending spree M&A

Read original source →